Phase two of a large clinical trial on a drug was recently completed that shows a reduction in plaque in the brain that could slow the progression of dementia. University of Nebraska Medical Center’s Dr. Dan Murman is with the Department of Neurological Sciences and says it is showing good promise.
Dr. Murman says, “At the highest dose with the drug, the people had about a 30 percent slowing of the progression of the disease compared to the placebo group on the amyloid PET imaging. The plaque you can see with these kind of PET scans were reduced. So, it reduced plaques and seemed to slow down progression. Not a cure but about a 30 percent slowing.”
Dr. Murman says there have been a lot of failures with this approach. They have learned they have been attacking the issue too late and some of the doses on the trials were too low. There are about five medicines that are currently moving through clinical trials. He says it is a hopeful sign that researchers are on the right track.
Dr. Murman expects to see little success but likely not a home run however there is initial encouraging signs.